妊娠期甲状腺过氧化物酶抗体阴性的亚临床甲状腺功能减退症对子代智力发育的影响
本研究纳入139名儿童,比较甲状腺过氧化物酶抗体(TPOAb)阴性、妊娠期亚临床甲状腺功能减退症(SCH-TPOAb-)母亲所生子女与对照组子女的智力发育。结果显示,TSH在4.0–10.0 mIU/L且未治疗的母亲,其子代发育商(DQ)较对照组低8.67分(p<0.001);妊娠8周前接受左甲状腺素治疗者与对照组无显著差异。
要点
- TSH 4.0–10.0 mIU/L未治疗的SCH-TPOAb-母亲子代2岁时DQ较对照组低8.67分。
- TSH 2.5–4.0 mIU/L未治疗者及接受治疗的两组子代DQ与对照组无显著差异。
- DQ及其分项与母亲TSH水平呈显著负相关(r=-0.417至-0.253)。
核心结论
- SCH-TPOAb-对子代智力发育的影响与母亲TSH水平相关。
- TSH 4.0–10.0 mIU/L的SCH-TPOAb-孕妇在妊娠8周前接受标准化治疗,可能显著改善约2岁子代的智力发育水平。
- 作者指出本研究为历史性队列研究,所分析数据为进一步研究提供基础,需要进一步开展大样本前瞻性干预试验来证实结论。
研究设计与样本
- 历史性队列研究,共招募139名儿童。
- 112名儿童的母亲为SCH-TPOAb-,27名儿童的母亲为甲状腺功能正常且TPOAb阴性。
- 按母亲妊娠期TSH水平及是否接受左甲状腺素(LT4)治疗分为四组:A组(2.5 mIU/L < TSH ≤4.0 mIU/L,n=31)和B组(4.0 mIU/L < TSH ≤10.0 mIU/L,n=26)母亲在妊娠8周前接受LT4治疗;C组(2.5 mIU/L < TSH ≤4.0 mIU/L,n=27)和D组(4.0 mIU/L < TSH ≤10.0 mIU/L,n=28)母亲未接受治疗。
- 对照组E组为27名儿童,其母亲妊娠期血清TSH <2.5 mIU/L且TPOAb阴性。
- 使用Gesell发育诊断量表评估2岁儿童的智力发育。
主要发现
- D组发育商(DQ)较E组低8.67分(p < 0.001)。
- D组粗大运动商、精细运动商、适应性商(ABQ)、语言商(LQ)和个体社交行为商(ISBQ)均显著低于E组。
- A组、B组、C组与E组之间DQ无显著差异(p > 0.05)。
- Spearman秩相关分析显示,DQ、精细运动商(FMQ)、ABQ、LQ和ISBQ与TSH水平呈显著负相关(r分别为-0.417、-0.253、-0.273、-0.436和-0.272;p < 0.05)。
- 多因素logistic回归分析显示,母亲受教育程度(短教育)、母亲受教育程度(中等教育)和TSH水平(4.0 mIU/L < TSH ≤10.0 mIU/L)均为影响子代智力发育的危险因素(p < 0.05)。
临床怎么用
- 作者认为,对TSH水平在4.0–10.0 mIU/L的SCH-TPOAb-孕妇,在妊娠8周前进行标准化治疗可能显著改善约2岁子代的智力发育水平。
局限性
- 本研究为历史性队列研究。
- 需要进一步开展大样本前瞻性干预试验来证实结论。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Background: The adverse impact of maternal negative TPOAb of gestational subclinical hypothyroidism (SCH-TPOAb-) on the development of the offspring has not yet been clearly identified. A lingering controversy exists over the treatment of SCH-TPOAb- diagnosed during pregnancy. Therefore, this study was designed to evaluate the intellectual development of children of mothers who had SCH-TPOAb-. Methods: A number of 139 children were recruited; 112 children were born to SCH TPOAb- and 27 children were born to euthyroid TPOAb- mothers. Based on the mothers' thyrotropin (TSH) levels during pregnancy and whether or not they received levothyroxine (LT4) treatment, the children were assigned to four groups: Group A (2.5 mIU/L < TSH ≤4.0 mIU/L, n = 31) and Group B (4.0 mIU/L < TSH ≤10.0 mIU/L, n = 26), whose mothers were treated with LT4 before eight gestational weeks, and Group C (2.5 mIU/L < TSH ≤4.0 mIU/L, n = 27) and Group D (4.0 mIU/L < TSH ≤10.0 mIU/L, n = 28), whose mothers received no treatment. A total number of 27 children whose mother's serum TSH was <2.5 mIU/L and were TPOAb- during their pregnancy served as the control group (Group E). The intellectual development of two-year-old children was assessed and compared using the Gesell Development Diagnosis Scale. Results: The developmental quotient (DQ) in Group D was 8.67 lower than this in Group E (p < 0.001). More specifically, gross motor quotient, fine motor quotient, adaptability quotient (ABQ), language quotient (LQ), and individual social behavior quotient (ISBQ) of DQ in Group D were significantly lower than those in Group E. No significant differences were observed in DQ among Group A, Group B, Group C, and Group E (p > 0.05). Spearman's rank correlation analysis showed that DQ, FMQ, ABQ, LQ, and ISBQ were significantly negatively correlated with the TSH level (r = -0.417, -0.253, -0.273, -0.436, and -0.272; p < 0.05). In addition, multivariate logistic regression analysis revealed that mothers' education (short education), mothers' education (medium education), and TSH level (4.0 mIU/L < TSH ≤10.0 mIU/L) were both risk factors affecting the intellectual development of the offspring (p < 0.05). Conclusion: The effects of the intellectual development of the offspring with SCH-TPOAb- are related to the level of TSH. Standardized treatment for SCH-TPOAb- pregnant women before eight gestational weeks, whose TSH level was from 4.0 to 10.0 mIU/L, may significantly improve the intellectual development levels of the approximately two-year-old offspring. Although our study was a historical cohort study, the data analyzed provide the foundation for further investigation. Further prospective intervention trials with large numbers of participants are needed to confirm our conclusions. The Clinical Trial Registration number is 2021-K-84-02.
引用
- Chen J, Zhu J, Huang X, et al. Subclinical Hypothyroidism with Negative for Thyroid Peroxidase Antibodies in Pregnancy: Intellectual Development of Offspring. Thyroid. 2022. PMID: 34915770. doi:10.1089/thy.2021.0374
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。